More tools:Markets·Screener·Research·Chat

Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) Financial Statements

Biodexa Pharmaceuticals plc American Depositary Shs
SIC 8731 · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
FIGI BBG00BLVW3G4
XNAS · usd
0.81▼ 0.02 (-2.86%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close0.83
Day's Range0.82 – 0.90
52-Week Range0.60 – 11.88
Volume93.3K
Avg Volume677.4K
Share Statistics
Shares Outstanding
Employees11
ExchangeXNAS
Listed2015-12-07
Share count as of December 31, 2025
Loading Income Statement…
Key questions about Biodexa Pharmaceuticals plc American Depositary Shs (BDRX)
What is Biodexa Pharmaceuticals plc American Depositary Shs's Market Cap?
Biodexa Pharmaceuticals plc American Depositary Shs's Market Cap is $182.2B, based on as-reported figures from SEC (XBRL) filings.
What is Biodexa Pharmaceuticals plc American Depositary Shs's Enterprise Value?
Biodexa Pharmaceuticals plc American Depositary Shs's Enterprise Value is $182.2B, based on as-reported figures from SEC (XBRL) filings.
What is Biodexa Pharmaceuticals plc American Depositary Shs's Revenue (TTM)?
Biodexa Pharmaceuticals plc American Depositary Shs's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Biodexa Pharmaceuticals plc American Depositary Shs's Net Income (TTM)?
Biodexa Pharmaceuticals plc American Depositary Shs's Net Income (TTM) is -$8.6M, based on as-reported figures from SEC (XBRL) filings.
What is Biodexa Pharmaceuticals plc American Depositary Shs's Diluted EPS (TTM)?
Biodexa Pharmaceuticals plc American Depositary Shs's Diluted EPS (TTM) is -0.00, based on as-reported figures from SEC (XBRL) filings.
What is Biodexa Pharmaceuticals plc American Depositary Shs's Net Debt?
Biodexa Pharmaceuticals plc American Depositary Shs's Net Debt is -$11.5M, based on as-reported figures from SEC (XBRL) filings.
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Profit or loss [abstract]
Revenue—
Non-Operating Income (Expense)
Research and development costs
Administrative costs
Loss from operations
Interest Income
Finance expense
Loss before tax
Taxation
Loss for the year attributable to the owners of the parent
Items that will or may be reclassified subsequently to profit or loss:
Exchange gains arising on translation of foreign operations
Total other comprehensive income net of tax
Total comprehensive loss attributable to the owners of the parent
Continuing operations
Earnings Per Share (Basic)
Earnings Per Share (Diluted)